OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Skin Injury reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,257 reports · 51 co-occurring drugs

As of the last recalculation, Skin Injury appears in 3,257 FAERS reports alongside 51 co-occurring drug terms. The strongest observed disproportionality signal is CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE (PRR 23.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Ciprofloxacin Hydrochloride And Hydrocortisone7623.924.0
Sulfur1813.713.7
Desoximetasone3411.511.5
Adapalene29011.111.1
Canagliflozin4710.210.2
Ciprofloxacin Hydrochloride1318.98.9
Ciprofloxacin1218.78.7
Panitumumab218.68.6
Salicylic Acid698.58.5
Crisaborole106.76.7
Psyllium Husk106.56.5
Doxepin106.36.3
Prasugrel Hydrochloride106.36.3
Human Immunoglobulin G206.26.2
Cephalexin205.95.9
Ribociclib295.95.9
Teriparatide1015.95.9
Rabeprazole195.55.5
Metformin Hydrochloride Tablets485.45.4
Metformin Hydrochloride Extended-Release Tablets485.45.4
Metformin Hydrochloride Tablet485.45.4
Metformin Hydrochloride485.25.2
Ciprofolxacin575.25.2
Ciprofloxacin Tablets575.25.2
Brimonidine Tartrate145.05.0
Secukinumab1194.94.9
Adrenalinum274.24.2
Etonogestrel314.24.2
Hydroxychloroquine484.24.2
Sulfasalazine484.04.0
Axicabtagene Ciloleucel63.93.9
Asfotase Alfa63.83.8
Ustekinumab573.63.6
Golimumab473.53.5
Oxybutynin153.33.3
Memantine73.33.3
Memantine Hydrochloride73.33.3
Certolizumab Pegol583.23.2
Sunitinib Malate182.92.9
Fremanezumab-Vfrm52.82.8
Tafamidis52.72.7
Etanercept2312.62.6
Belimumab122.42.4
Apremilast522.32.3
Abatacept482.22.2
Nemolizumab-Ilto42.02.0
Glatiramer Acetate181.91.9
Benralizumab61.91.9
Guselkumab91.61.6
Ixekizumab71.21.2
Dupilumab801.11.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.